Clinical Study

Risk Factors for Preterm Birth among HIV-Infected Tanzanian Women: A Prospective Study

Rachel M. Zack,1 Jenna Golan,2 Said Aboud,3 Gernard Msamanga,4 Donna Spiegelman,1,2,5 and Wafaie Fawzi1,2,6

1 Department of Epidemiology, Harvard School of Public Health, 1633 Tremont Street, Boston, MA 02115, USA
2 Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
3 Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
4 Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
5 Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
6 Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA

Correspondence should be addressed to Rachel M. Zack; rmzack@gmail.com

Received 22 June 2014; Revised 10 September 2014; Accepted 12 September 2014; Published 28 September 2014

Academic Editor: Everett Magann

Copyright © 2014 Rachel M. Zack et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Premature delivery, a significant cause of child mortality and morbidity worldwide, is particularly prevalent in the developing world. As HIV is highly prevalent in much of sub-Saharan Africa, it is important to determine risk factors for prematurity among HIV-positive pregnancies. The aims of this study were to identify risk factors of preterm (<37 weeks) and very preterm (<34 weeks) birth among a cohort of 927 HIV positive women living in Dar es Salaam, Tanzania, who enrolled in the Tanzania Vitamin and HIV Infection Trial between 1995 and 1997. Multivariable relative risk regression models were used to determine the association of potential maternal risk factors with premature and very premature delivery. High rates of preterm (24%) and very preterm birth (9%) were found. Risk factors (adjusted RR (95% CI)) for preterm birth were mother <20 years (1.46 (1.10, 1.95)), maternal illiteracy (1.54 (1.10, 2.16)), malaria (1.42 (1.11, 1.81)), Entamoeba coli (1.49 (1.04, 2.15)), no or low pregnancy weight gain, and HIV disease stage ≥2 (1.41 (1.12, 1.50)). Interventions to reduce pregnancies in women under 20, prevent and treat malaria, reduce Entamoeba coli infection, and promote weight gain in pregnant women may have a protective effect on prematurity.

1. Introduction

Preterm delivery is recognized as a significant cause of child mortality and morbidity worldwide. Preterm birth is the leading cause of neonatal mortality [1]. It is estimated that preterm birth is the direct cause of 29% of deaths in children under 28 days and 11% of deaths in children under 5 years [1–3].

Prematurity disproportionately affects newborns in resource-constrained countries, where it is both more common and more often leads to adverse health outcomes. A systematic review from 2010 reports that 7.5% and 11.9% of births in developed countries and in Africa, respectively, were preterm [4]. In Tanzania, 11% of births are premature and prematurity is the second leading cause of neonatal death [5]. In a study of hospitalized neonates in Tanzania, the neonatal mortality rate for preterm infants was twice as high as that for full-term infants, 26% versus 13% [6].

Expending extra resources on additional medical care for pregnant women with risk factors for prematurity could reduce the incidence of prematurity. Not only would this have immediate benefits, such as reducing neonatal mortality, but it could also reduce the risk of chronic disease due to preterm delivery throughout the life course [7, 8]. This could substantially lower long-term health expenditures.

The prevalence of HIV infection among Tanzanian women is estimated to be 6.6% [9]. Given the significant proportion of pregnant women who are HIV-infected in
some regions of the world, it is important to determine not only the risk factors for prematurity among the general population but also risk factors for prematurity among HIV-infected women, because such factors could be distinct from those in HIV uninfected women.

As the 2015 deadline of the Millennium Development Goals (MDGs) draws near, it is clear that MDG 4, the goal of reducing the under-five child mortality rate by two-thirds between 1990 and 2015, cannot be reached unless efforts are drastically increased [10]. While under-five mortality is declining in many countries, neonatal mortality still lags behind. Since preterm birth is responsible for 11% of under-five mortality worldwide, knowledge of risk factors for prematurity may help the global community to reach MDG 4 [11]. This paper aims to contribute to the evidence base needed for a reduction in premature delivery by finding determinants of preterm and very preterm birth through the analysis of a cohort of 927 HIV-infected Tanzanian women. We examined potential risk factors for preterm delivery, many of which were previously found to be associated with preterm delivery in healthy populations.

2. Methods

2.1. Study Population and Design. Study participants were enrolled in a trial of vitamin supplements on pregnancy outcomes and HIV disease progression. Participants were HIV-infected pregnant women living in Dar es Salaam, Tanzania. Women were recruited from four prenatal clinics. They were enrolled in the study between April 1995 and July 1997. Inclusion criteria included 12 to 27 weeks gestation, intention to continue residing in Dar es Salaam for at least one year following delivery, World Health Organization (WHO) HIV disease stages 1–3, and informed consent to be randomized to a treatment regimen. The study has previously been described in further detail [12–15].

Of 1078 women enrolled in the trial, 949 had a live birth with known gestational age at delivery. For the prematurity analyses, we excluded 22 additional women because of missing data on key potential risk factors for preterm birth including age, maternal literacy, maternal malaria, HIV disease stage, hypertension status, height, or at least two measures of weight during pregnancy. None of the women reported smoking during pregnancy. This resulted in a sample of 927 pregnant women.

Consistent with the Tanzanian Ministry of Health’s standard of prenatal care at the time of the study, study participants were provided with anemia and malaria prophylaxis during pregnancy. During pregnancy, all study participants received daily doses of 400 mg of folic acid for anemia prophylaxis and weekly doses of 500 mg of chloroquine phosphate for malaria prophylaxis. Study participants were treated for hypertension and syphilis during pregnancy if found to have either disease. Study participants did not receive antiretrovirals (ARVs), as they were not available in Tanzania at the time of the study.

The trial was approved by the Research and Publications Committee of Muhimbili University of Health and Allied Sciences, the ethics committee of the Tanzania Ministry of Health’s National AIDS Control Program, and the Institutional Review Board of the Harvard School of Public Health.

2.2. Measurements. Premature was defined as birth at fewer than 37 weeks of gestation and very premature was defined as fewer than 34 weeks of gestation. Gestational age was based on last menstrual period (LMP), which was self-reported by the participant at both screening and enrollment. Fundal height was measured as the distance, in centimeters, from the top of the pubic bone to the top of the uterus by trained doctors during the screening visit.

Anthropometric measurements, genital swabs, and blood, urine, and stool samples were collected at enrollment. These specimens were used to diagnose malaria, sexually transmitted infections (STIs), and parasitic infections and to measure micronutrient levels, hemoglobin concentration, HIV viral load, and CD4 cell count. By design, vitamin A, vitamin E, viral load, parasitic infections, and STIs were only measured in a subsample of study participants.

The following STIs were tested for at enrollment: trichomoniasis, gonorrhea, syphilis, and vaginal candidiasis. Syphilis was diagnosed as active if syphilis antibodies from sera were found to be present by both the Venereal Disease Research Laboratory (VDRL; Murex Diagnostic, Dartford, United Kingdom) and Treponema pallidum haemagglutination (TPHA; Fijurebio, Tokyo, Japan) tests. Gonorrhea was diagnosed based on a culture of the genital swab to detect Neisseria gonorrhoea and Trichomonas vaginalis was diagnosed based upon wet mounts that were prepared and examined using microscopy. Vaginal candidiasis was diagnosed clinically by physician exam.

The following intestinal parasitic infections were tested for at enrollment: Ascaris lumbricoides, Cryptosporidium parvum, Entamoeba coli, Entamoeba histolytica, Enterobius, Giardia lamblia, hookworm, isospora, microsporidia, Strongyloides stercoralis, Taenia, and Trichuris trichiura. Stool samples were examined macroscopically for the previously mentioned worms and microscopically using saline and iodine wet mount and the formalin-ether concentration technique for larvae, ova, and cysts.

Malaria was diagnosed by use of thick-smear blood films stained with Giemsa. Vitamin A deficiency was defined as plasma vitamin A <20 μg/dL. Low vitamin E levels were defined as plasma vitamin E <9.7 μmol/L. CD4 cell counts were dichotomized by <200 cell/mm³. We categorized hemoglobin levels according to three cutpoints: 7.0, 8.5, and 11.0 g/L. The WHO defines anemia in pregnancy as a hemoglobin concentration below 11 g/dL [16]. Prehypertension was defined as systolic blood pressure (SBP) ≥120 or diastolic blood pressure (DBP) ≥80 and hypertension was defined as SBP ≥140 or DBP ≥90 [17]. Selenium and mid-upper arm circumference (MUAC) were categorized by quartile. WHO HIV disease stage was dichotomized (stage < 2 versus stage ≥ 2) because of the limited number of women with HIV stage >2.

Trained research nurses interviewed study participants at enrollment. Maternal age and relationship status were
self-reported. Maternal age at conception was estimated by subtracting gestational age at enrollment from maternal age at enrollment. Having a partner was defined as self-report of being married or cohabiting.

2.3. Statistical Analyses. Prematurity status, the outcome variable, was determined based on self-reported LMP. In order to validate the quality of LMP as a measure of gestational age we performed a supplemental analysis where we calculated the Spearman correlation between gestational ages based on LMP and fundal height.

Risk factors measured at enrollment that we examined were mother’s age at conception, having no partner, being illiterate, mid-upper arm circumference (MUAC), height, vitamin A, vitamin E, selenium, hemoglobin, malaria, parasitic infections, STIs, HIV disease stage ≥ 2, CD4 cell count, and viral load. Whether or not the pregnancy resulted in twins and weight change during pregnancy were also included as exposures. Although the Tanzania Vitamin and HIV Infection Trial found that multivitamins reduced the risk of very preterm delivery [12], we did not adjust for assigned vitamin regimen because vitamin regimen was randomized and thus did not confound the relationships between the risk factors we examined and preterm delivery.

Weight change during pregnancy was calculated for each individual by using linear regression to regress weight on week of gestation [18–20]. Weight change was then categorized into three groups: no gain (≤0 grams per week), gain below the 25th percentile, and gain at or above the 25th percentile.

Missing indicators were created for each of the parasitic infections, each of the STIs, viral load, CD4 cell count, vitamin A deficiency, vitamin E, selenium, hemoglobin, and MUAC [21].

Unadjusted and adjusted relative risk regression models were run to calculate relative risks (RRs) and 95% confidence intervals (CIs) [22]. Log-binomial regression was used for all unadjusted regressions. Poisson was used for the adjusted regressions because the adjusted log-binomial regressions did not converge. Each regression was run twice, once with preterm versus full term as the dependent variable and again with very preterm versus full term as the dependent variable. Deliveries of 34–<37 weeks were excluded from the very preterm versus full term analysis. Explanatory variables were included in the adjusted models if the P-value in the unadjusted model was less than 0.2 [23]. Wald tests for trend were calculated for categorical variables by taking the median value of each category and setting missing values to the overall median. Wald tests were calculated for dichotomous and continuous variables.

We calculated a Spearman correlation coefficient comparing gestational age as measured by LMP and fundal height on 1077 women. The analysis included data on all trial participants with a known LMP and fundal height at the screening visit, excluding only one woman who was missing data on LMP.

A P value of ≤0.05 was considered to be statistically significant. All statistical analyses were performed using SAS software 9.3 (SAS Institute, Inc., http://www.sas.com, Cary, North Carolina).

3. Results

The median gestational age at enrollment was 21 weeks (IQR 18–23). The median gestational age at delivery was 39 weeks (IQR 37–41). Seventy-six percent of deliveries were full-term, 24% were premature and 9% were very premature. The characteristics of the cohort are shown in Table 1.

The results of unadjusted and adjusted relative risk regressions assessing the relationships of maternal factors and the risk for preterm versus full-term deliveries are shown in Table 2. After adjustment, maternal age less than 20 years (RR, 1.46; 95% CI, 1.10–1.95), maternal illiteracy (RR, 1.54; 95% CI, 1.10–2.61), low weight gain during pregnancy (P for trend = 0.006), malaria (RR, 1.42; 95% CI, 1.11–1.81), Entamoeba coli infection (RR, 1.49; 95% CI, 1.04–2.15), and HIV disease stage ≥ 2 (RR, 1.41; 95% CI, 1.12–1.79), and prehypertension or hypertension (RR, 1.26; 95% CI, 1.00–1.59) were significantly and independently associated with increased risk of preterm delivery. After adjustment, vitamin A deficiency, Entamoeba histolytica infection, and carrying twins were all associated with an increased risk of preterm delivery with borderline significance.

The results of unadjusted and adjusted relative risk regressions comparing maternal factors for very preterm versus full-term deliveries are presented in Table 3. Maternal age less than 20 years (RR, 1.91; 95% CI, 1.21–3.03), small MUAC (P for trend = 0.03), low weight gain during pregnancy (P for trend = 0.0005), malaria (RR, 1.81; 95% CI, 1.19–2.76), Entamoeba coli infection (RR, 2.38; 95% CI, 1.38–4.09), and Entamoeba histolytica infection (RR, 2.62; 95% CI, 1.09–6.28), and HIV disease stage ≥ 2 (RR, 1.68; 95% CI, 1.11–2.53) were significantly and independently associated with increased risk of preterm delivery. Maternal illiteracy was associated with increased risk of very preterm delivery with borderline significance.

For the analysis, we dichotomized maternal age with a cutoffpoint at 20 years. We chose not to include an age group for older mothers because analyses showed that the risk of prematurity in mothers aged 30 and older was not significantly greater than the risk of prematurity in mothers aged 20 to 30 (data not shown).

There may be concern that gestational age based on self-reported LMP is potentially unreliable. However, we found a correlation of 0.78 (95% CI, 0.76–0.80) between gestational age at screening based on LMP and fundal height, suggesting that, for this population, self-reported LMP can be used as a reasonable measure of gestational age.

4. Discussion

4.1. Main Findings. Our study found that HIV disease stage ≥ 2, no or low weight gain during pregnancy, Entamoeba coli, malaria, and maternal age less than 20 years were significantly associated with risk of preterm and very preterm
Table 1: Study population characteristics, N = 927*

| Characteristic                          | N (%) or median | IQR       |
|----------------------------------------|-----------------|-----------|
| Preterm births (<37 wks)               | 227 (24%)       |           |
| Very preterm births (<34 wks)          | 87 (9%)         |           |
| Gestational age at enrollment (weeks)  | 21 [18, 23]     |           |
| Gestational age at birth (weeks)       | 39 [37, 41]     |           |
| **Sociodemographic**                   |                 |           |
| Maternal age at conception (years)     | 25 [22, 29]     |           |
| <20                                    | 96 (10%)        |           |
| No partner                             | 103 (11%)       |           |
| Illiterate                             | 70 (8%)         |           |
| **Nutrition and Anthropometric**       |                 |           |
| Plasma vitamin A (μg/dL)               | 23.4 [179, 30.2] |          |
| <20                                    | 246 (34%)       |           |
| Plasma vitamin E (μmol/L)              | 9.6 [8.0, 11.4]  |          |
| <9.7                                   | 368 (51%)       |           |
| Selenium (mg/mL)                       | 0.12 [0.11, 0.14]|         |
| <0.11                                  | 218 (26.49%)    |           |
| 0.11-0.12                              | 148 (12.98%)    |           |
| 0.12–0.14                              | 250 (30.38%)    |           |
| ≥0.14                                  | 207 (25.15%)    |           |
| Hemoglobin (g/dL)                      | 9.5 [8.4, 10.5]  |          |
| <7.0                                   | 59 (6%)         |           |
| 7.0–8.4                                | 188 (21%)       |           |
| 8.5–10.9                               | 508 (56%)       |           |
| ≥11.0                                  | 112 (12%)       |           |
| Mid-upper arm circumference (cm)       | 25.0 [23.5, 27.5]|         |
| ≤23.5                                  | 225 (26%)       |           |
| 23.6–25.0                              | 203 (24%)       |           |
| 25.1–27.5                              | 220 (26%)       |           |
| >27.5                                  | 203 (24%)       |           |
| Weight gain (g per week)               | 255 [116, 380]  |           |
| ≤0                                     | 112 (12%)       |           |
| 1–119                                  | 126 (14%)       |           |
| ≥120                                   | 689 (74%)       |           |
| Height (cm)                            | 156 [152, 160]  |           |
| <150                                   | 90 (10%)        |           |
| **Infections**                         |                 |           |
| Malaria                                | 176 (19%)       |           |
| Hookworm                               | 92 (12%)        |           |
| *Entamoeba coli*                       | 69 (9%)         |           |
| *Ascaris lumbricoides*                 | 43 (6%)         |           |
| *Cryptosporidium parvum*               | 34 (4%)         |           |
| *Entamoeba histolytica*                | 15 (2%)         |           |
| *Strongyloides stercoralis*            | 14 (2%)         |           |
| *Trichuris trichiura*                  | 9 (1%)          |           |
| *Giardia lamblia*                      | 4 (1%)          |           |
| *Enterobius*                           | 0 (0%)          |           |
| *Isospora*                             | 0 (0%)          |           |
| *Microsporidia*                        | 0 (0%)          |           |
| *Taenia*                               | 0 (0%)          |           |

Table 1: Continued.

| Characteristic                          | N (%) or median | IQR       |
|----------------------------------------|-----------------|-----------|
| Trichomoniasis                         | 232 (25%)       |           |
| Syphilis                               | 44 (6%)         |           |
| Vaginal candidiasis                    | 41 (6%)         |           |
| Gonorrhea                              | 9 (1%)          |           |
| HIV/AIDS                               |                 |           |
| WHO HIV disease stage ≥ 2              | 189 (20%)       |           |
| CD4 count (cells/mm³)                  | 402 [275, 530]  |           |
| <200                                   | 112 (13%)       |           |
| Viral load (copies/mL)                 | 47819 [11626, 146135] |       |
| ≥50,000                                | 193 (50%)       |           |
| **Other clinical variables**           |                 |           |
| Twins                                  | 22 (2%)         |           |
| Diastolic blood pressure (mmHg)        | 70 [60, 70]     |           |
| Systolic blood pressure (mmHg)         | 110 [100, 110]  |           |
| Prehypertension or hypertension       | 259 (28%)       |           |

AIQR: interquartile range.

*Not all numbers add up to 927 due to missing data.

bSystolic blood pressure > 120 mmHg or diastolic blood pressure > 80 mmHg.

4.2. Strengths and Limitations. Although there have been several studies on risk factors for premature delivery, this study is unique in that it is based upon a large sample of HIV-infected, ART-naive pregnant women in sub-Saharan Africa. However, there are some potential limitations to our study and analyses. Many of the potential risk factors we examined were only measured at enrollment and not throughout the pregnancy. Additional useful information would have been obtained if lab samples had been taking throughout participants’ pregnancies, since this would have provided more complete data on parasitic infections, STIs, HIV disease progression, and nutritional status throughout pregnancy.

The potential lack of reliability of using LMP to estimate gestational age is a limitation to our study, although this approach is used frequently, both clinically and for research, in sub-Saharan Africa given the expense and lack of access to ultrasound machines. We expect that the definition of prematurity will be misclassified in a random way with respect to various strata of a particular risk factor in our analyses. Thus, we expect that our findings are biased towards the null because nondifferential exposure of a binary outcome will bias the results towards the null [24]. We found gestational age based on fundal height and LMP to be highly correlated. However, ultrasound, not fundal height measurements is the gold standard for measuring gestational age. Fundal height is thought to be accurate to 1–3 weeks. A future study...
Table 2: Risk factors for preterm birth (<37 weeks versus ≥37 weeks), $N = 927$.

| Characteristic                              | Unadjusted       | Adjusted*       |
|---------------------------------------------|------------------|------------------|
|                                             | RR [95% CI]      | P value          | RR [95% CI]      | P value          |
| Sociodemographic                            |                  |                  |                  |                  |
| Age < 20 at conception                      | 1.58 [1.18, 2.11] | 0.002            | 1.47 [1.10, 1.97] | 0.01             |
| No partner                                  | 1.17 [0.84, 1.63] | 0.35             |                  |                  |
| Illiterate                                  | 1.58 [1.14, 2.20] | 0.006            | 1.53 [1.09, 2.15] | 0.01             |
| Nutrition                                   |                  |                  |                  |                  |
| Plasma vitamin A < 20 (μg/dL)               | 1.24 [1.19, 1.96] | 0.0008           | 1.25 [0.97, 1.62] | 0.08             |
| Plasma vitamin E < 9.7 (μmol/L)             | 0.88 [0.69, 1.13] | 0.31             |                  |                  |
| Selenium (mg/mL)                            |                  |                  |                  |                  |
| <0.11                                       | 1.37 [0.97, 1.96] |                  | 1.40 [0.98, 2.00] |                  |
| 0.11–0.12                                   | 1.15 [0.77, 1.73] |                  | 1.11 [0.74, 1.65] |                  |
| 0.12–0.14                                   | 1.39 [0.98, 1.95] |                  | 1.48 [1.05, 2.08] |                  |
| ≥0.14                                       | Reference        |                  | Reference        |                  |
| Hemoglobin (g/dL)                           |                  | 0.11             |                  | 0.90             |
| <7.0                                        | 1.29 [0.83, 2.01] |                  | 0.98 [0.64, 1.52] |                  |
| 7.0–8.4                                     | 1.05 [0.74, 1.49] |                  | 0.90 [0.63, 1.28] |                  |
| 8.5–10.9                                    | 0.82 [0.60, 1.11] |                  | 0.78 [0.58, 1.07] |                  |
| ≥11.0                                       | Reference        |                  | Reference        |                  |
| Mid-upper arm circumference (cm)            |                  | 0.19             |                  | 0.23             |
| ≤23.5                                       | 1.29 [0.92, 1.81] |                  | 1.32 [0.93, 1.87] |                  |
| 23.6–25.0                                   | 0.95 [0.66, 1.39] |                  | 0.91 [0.63, 1.33] |                  |
| 25.1–27.5                                   | 1.11 [0.78, 1.58] |                  | 1.07 [0.75, 1.53] |                  |
| >27.5                                       | Reference        |                  | Reference        |                  |
| Weight gain (g per week)                    |                  | <0.0001          |                  | 0.006            |
| ≤0                                          | 1.95 [1.51, 2.53] |                  | 1.60 [1.20, 2.14] |                  |
| 1–120                                       | 1.18 [0.85, 1.65] |                  | 1.12 [0.81, 1.57] |                  |
| ≥120                                        | Reference        |                  | Reference        |                  |
| Height < 150 cm                             | 0.95 [0.64, 1.40] | 0.79             |                  |                  |
| Infections                                  |                  |                  |                  |                  |
| Malaria                                     | 1.53 [1.20, 1.96] | 0.0006           | 1.41 [1.10, 1.81] | 0.006            |
| Hookworm                                    | 1.30 [0.92, 1.84] | 0.13             | 1.19 [0.83, 1.70] | 0.34             |
| *Entamoeba coli*                            | 1.49 [1.04, 2.14] | 0.03             | 1.49 [1.04, 2.15] | 0.03             |
| *Ascaris lumbricoides*                      | 1.21 [0.73, 1.99] | 0.46             |                  |                  |
| *Cryptosporidium parvum*                    | 0.88 [0.45, 1.72] | 0.70             |                  |                  |
| *Entamoeba histolytica*                     | 1.73 [0.92, 3.27] | 0.09             | 1.79 [0.99, 3.26] | 0.06             |
| *Strongyloides stercoralis*                 | 1.23 [0.53, 2.84] | 0.63             |                  |                  |
| *Trichuris trichiura*                       | 1.44 [0.56, 3.65] | 0.45             |                  |                  |
| Trichomoniasis                              | 1.18 [0.92, 1.52] | 0.19             | 1.13 [0.88, 1.45] | 0.35             |
| Syphilis                                    | 1.28 [0.80, 2.05] | 0.31             |                  |                  |
| Vaginal candidiasis                         | 1.10 [0.66, 1.85] | 0.72             |                  |                  |
| Gonorrhea                                   | 1.83 [0.88, 3.85] | 0.11             | 1.68 [0.84, 3.35] | 0.14             |
| HIV/AIDS                                    |                  |                  |                  |                  |
| WHO HIV disease stage ≥ 2                   | 1.60 [1.26, 2.03] | 0.0001           | 1.40 [1.11, 1.78] | 0.005            |
| CD4 count < 200 cells/mm^3                  | 0.92 [0.64, 1.32] | 0.65             |                  |                  |
| Viral load ≥ 50,000 copies/mL               | 1.02 [0.74, 1.42] | 0.89             |                  |                  |
| Other clinical variables                    |                  |                  |                  |                  |
| Twins                                       | 1.50 [0.85, 2.64] | 0.16             | 1.85 [0.94, 3.66] | 0.07             |
| Prehypertension or hypertension^b*          | 1.25 [0.98, 1.58] | 0.07             | 1.27 [1.01, 1.60] | 0.04             |

ARR: risk ratio; CI: confidence interval.

*Adjusted for age < 20 years, literacy, plasma vitamin A < 20 μg/dL, selenium, mid-upper arm circumference, weight gain, malaria, hookworm, *Entamoeba coli*, *Entamoeba histolytica*, trichomoniasis, gonorrhea, WHO HIV disease stage ≥ 2, twins, and prehypertension or hypertension.

^bSystolic blood pressure >120 mmHg or diastolic blood pressure >80 mmHg.
Table 3: Risk factors for very preterm birth (<34 weeks versus ≥37 weeks), N = 787.

| Characteristic                                      | Unadjusted          |           | Adjusted\(^a\)          |           |
|-----------------------------------------------------|---------------------|-----------|--------------------------|-----------|
|                                                     | RR [95% CI]         | P value   | RR [95% CI]              | P value   |
| Sociodemographic                                    |                     |           |                          |           |
| Age < 20 at conception                              | 2.21 [1.37, 3.55]   | 0.001     | 1.94 [1.22, 3.06]        | 0.005     |
| No partner                                          | 1.20 [0.66, 2.16]   | 0.55      |                          |           |
| Illiterate                                          | 1.93 [1.09, 3.41]   | 0.02      | 1.66 [0.91, 3.02]        | 0.10      |
| Nutrition                                           |                     |           |                          |           |
| Plasma vitamin A < 20 (µg/dL)                       | 1.89 [1.24, 2.87]   | 0.003     | 1.38 [0.89, 2.13]        | 0.15      |
| Selenium (mg/mL)                                    | 0.003 [<0.01, 0.58] | 0.24      |                          |           |
| <0.11                                               | 1.64 [0.87, 3.09]   |           |                          |           |
| 0.11–0.12                                           | 1.13 [0.53, 2.40]   |           |                          |           |
| 0.12–0.14                                           | 1.82 [1.00, 3.32]   |           |                          |           |
| ≥0.14                                               | Reference           |           | Reference                |           |
| Hemoglobin (g/dL)                                   |                     | 0.45      |                          |           |
| <7.0                                                | 0.72 [0.43, 1.23]   |           |                          |           |
| 7.0–8.4                                             | 0.72 [0.43, 1.23]   |           |                          |           |
| 8.5–10.9                                            | 1.12 [0.63, 2.01]   |           |                          |           |
| ≥11.0                                               | Reference           |           | Reference                |           |
| Mid-upper arm circumference (cm)                    |                     | 0.03      | 0.03                     |           |
| ≤23.5                                               | 1.90 [0.99, 3.67]   |           | 2.07 [1.03, 4.16]        |           |
| 23.6–25.0                                           | 1.50 [0.75, 3.00]   |           | 1.50 [0.74, 3.06]        |           |
| 25.1–27.5                                           | 1.10 [0.52, 2.32]   |           | 1.03 [0.49, 2.20]        |           |
| >27.5                                               | Reference           |           | Reference                |           |
| Weight gain (g per week)                            |                     | <0.0001   | 0.0005                   |           |
| ≤0                                                  | 3.21 [2.06, 5.00]   |           | 2.32 [1.36, 3.96]        |           |
| 1–120                                               | 1.78 [1.05, 3.03]   |           | 1.85 [1.05, 3.25]        |           |
| ≥120                                                | Reference           |           | Reference                |           |
| Height < 150 cm                                     | 0.93 [0.47, 1.86]   | 0.84      |                          |           |
| Infections                                          |                     |           |                          |           |
| Malaria                                             | 2.03 [1.34, 3.07]   | 0.0009    | 1.87 [1.20, 2.89]        | 0.005     |
| Hookworm                                            | 1.18 [0.61, 2.27]   | 0.63      |                          |           |
| Entamoeba coli                                      | 2.34 [1.36, 4.02]   | 0.002     | 2.38 [1.38, 4.09]        | 0.002     |
| Ascaris lumbricoides                                | 1.34 [0.58, 3.13]   | 0.49      |                          |           |
| Cryptosporidium parvum                              | 0.64 [0.17, 2.50]   | 0.53      |                          |           |
| Entamoeba histolytica                               | 2.44 [0.89, 6.66]   | 0.08      | 2.62 [1.09, 6.28]        | 0.03      |
| Strongyloides stercoralis                           | 0.86 [0.13, 5.65]   | 0.88      |                          |           |
| Trichuris trichiura                                 | No data             |           |                          |           |
| Trichomoniasis                                      | 1.30 [0.84, 1.99]   | 0.24      |                          |           |
| Syphilis                                            | 1.34 [0.58, 3.13]   | 0.49      |                          |           |
| Vaginal candidiasis                                 | 0.82 [0.27, 2.45]   | 0.72      |                          |           |
| Gonorrhea                                           | 2.61 [0.80, 8.57]   | 0.11      | 2.72 [0.86, 8.58]        | 0.09      |
| HIV/AIDS                                            |                     |           |                          |           |
| WHO HIV disease stage ≥ 2                           | 2.09 [1.39, 3.14]   | 0.0004    | 1.67 [1.11, 2.51]        | 0.01      |
| CD4 count < 200 cells/mm³                            | 0.72 [0.36, 1.45]   | 0.36      |                          |           |
| Viral load ≥ 50,000 copies/mL                       | 0.79 [0.46, 1.36]   | 0.40      |                          |           |
| Other clinical variables                            |                     |           |                          |           |
| Twins                                               | 2.06 [0.85, 5.00]   | 0.11      | 1.86 [0.68, 5.07]        | 0.22      |
| Prehypertension or hypertension\(^b\)              | 1.16 [0.76, 1.79]   | 0.49      | 1.22 [0.81, 1.85]        | 0.33      |

ARR: risk ratio; CI: confidence interval.

\(^a\) Adjusted for age < 20 years, literacy, plasma vitamin A < 20 µg/dL, mid-upper arm circumference, weight gain, malaria, Entamoeba coli, Entamoeba histolytica, gonorrhea, WHO HIV disease stage ≥ 2, twins, and prehypertension or hypertension.

\(^b\) Systolic blood pressure > 120 mmHg or diastolic blood pressure > 80 mmHg.
comparing gestational age based on LMP versus ultrasound in a developing country context, where recall of LMP may be especially inaccurate, could provide further information on the reliability of gestational age based on self-reported LMP.

Our study took place before zidovudine (AZT) and other ARVs were in use in Tanzania, allowing us to identify risk factors for prematurity among children born to ARV-naive HIV-positive women. The use of highly active antiretroviral therapy (HAART), but not AZT monotherapy, during pregnancy has been shown to increase the risk of preterm delivery [25]. In 2012, only 71% of HIV-infected pregnant women in Tanzania were receiving ARVs for prevention of mother-to-child transmission (PMTCT) [26]. This indicates that in Tanzania the risk factors we have found for preterm delivery in HIV-infected women are directly relevant for 29% of the pregnancies in HIV-infected women. A review of PMTCT coverage in 108 countries between 2007 and 2009 found that only 35% of HIV-infected pregnant women received PMTCT [27]. The WHO estimates that in 21 priority countries in sub-Saharan Africa in 2012, only 64% of HIV-infected pregnant women received any ARVs for PMTCT [28]. Among these 21 countries, PMTCT coverage ranged from 13% in the Democratic Republic of the Congo to >95% in both Botswana and Zambia [28].

Furthermore, the WHO guidelines recommend that low-income countries choose from one of three options (A, B, or B+) for PMTCT. The guidelines suggest that all patients with a CD4 count of <350 cells/mm$^3$ begin HAART and that pregnant women with CD4 counts >350 cells/mm$^3$ be provided with either option A, B, or B+. Option A is the provision of AZT monotherapy beginning at no sooner than 14 weeks gestation. Option B is the provision of HAART beginning at no sooner than 14 weeks gestation. Option B+ is the provision of HAART as soon as HIV infection is diagnosed. While some countries have adopted option B or B+ for prevention of mother-to-child transmission of HIV, several countries have opted to adopt Option A of the WHO guidelines whereby women receive HAART only if they are advanced in their disease. For example, Kenya has adopted a combination of options A and B, in which health centers adopt option A if they do not have the capacity to adopt option B [29]. In these settings, a majority of pregnant women are in early stages of disease and are thus not initiated on triple ARVs, and for whom our findings are applied.

4.3. Interpretation. Preterm delivery and very preterm delivery were analyzed as separate outcomes for two reasons. First, because very preterm delivery leads to more severe health outcomes than preterm delivery, identification of differing risk factors would make possible the targeting of available resources toward very preterm delivery prevention. However, we found that risk factors for very preterm and preterm deliveries were similar. Our results suggest that the same interventions can be used to reduce both preterm and very preterm deliveries. Furthermore, analyzing preterm and very preterm deliveries separately provided a sensitivity analysis. The regression analysis of very preterm deliveries excluded deliveries between 34 and 37 weeks, reducing misclassification bias that may be associated with gestational age assessment.

Because very preterm deliveries are a subset of preterm deliveries, they have a smaller sample size, resulting in larger standard errors and $P$ values, and wider confidence intervals. Many of the point estimates are larger in the very preterm regression. This may be because there is less misclassification bias due to incorrectly estimated gestational age. Deliveries with a reported gestational age of less than 34 weeks were more likely to be correctly classified as preterm than those with a reported gestational age of less than 37 weeks.

The rate of prematurity that we observed, 24%, is higher than that found in other HIV-infected populations. A study of 1626 HIV-positive Nigerian women from 2004–2010 found a preterm delivery rate of 11.1% [30]. This may partially be due to improvements in nutrition and maternal health from 1995–1997 to 2004–2010. A study in the United States in the early 1990’s found that 19% of infants born to HIV-infected mothers were premature [31]. This difference is likely due, in part, to better healthcare in the US.

We found lack of weight gain during pregnancy to be associated with preterm and very preterm delivery. Weight gain is a marker of maternal nutritional status, and thus no or low weight gain during pregnancy could be a marker of inadequate nutrition during pregnancy. However, this finding may be due to reverse causality, as it is unknown whether lack of weight gain caused the premature delivery or the premature delivery led to less time for gestational weight gain.

We found that HIV disease stage $\geq 2$ at enrollment increased the risk of prematurity. However, we did not find any further association between prematurity and either CD4 cell count or viral load. A study in South Africa found no effect of HIV-infection in ART-naive women on prematurity [32]. However, a previous study in China did report an effect of CD4 count and viral load on prematurity [33].

We found younger maternal age, but not older maternal age, to be a risk factor for preterm birth. Women younger than 20 years were more likely to deliver preterm compared to women 20 years and older. However, women 30 years of age and older were not found to be at a higher risk of premature delivery compared to women aged 20–30. The result that young mothers are at an increased risk for premature delivery has also been found in studies in other sub-Saharan African countries such as Cameroon [34], but not Zimbabwe [35]. The result that older maternal age is not associated with premature delivery was also found in a Turkish study that found adolescent pregnancy to be a weak risk factor for prematurity but did not find maternal age of 39 and older to increase the risk of prematurity [36]. However, a study in the US found women aged 30–34 and aged 35 and older to be at an increased risk for premature delivery compared to women aged 25–29 [37].

5. Conclusion

As the preventable and treatable major killers of children such as malaria, diarrheal disease, and respiratory disease are
increasingly managed, with the presumption that mortality from these causes will decrease, the proportion of child mortality due to premature birth will increase. In order to further reduce needless child deaths, it will be important to reduce the modifiable determinants of preterm birth so as to increase the percentage of children that are born full-term. Interventions to promote nutritional status and to slow HIV disease progression are likely to be critical for reducing the risk of prematurity.

**Ethical Approval**

The study was approved by the Research and Publications Committee of Muhimbili University of Health and Allied Sciences, the ethics committee of the Tanzania Ministry of Health’s National AIDS Control Program, and the Institutional Review Board of the Harvard School of Public Health (no. 10399).

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Authors’ Contribution**

Wafaie Fawzi proposed the study question and edited the paper. Said Aboud contributed to study design and data collection and edited the paper. Donna Spiegelman edited the paper and provided statistical advice. Gerard Msamanga contributed to study design and execution of the fieldwork and edited the paper. Rachel M. Zack conducted the analyses, interpreted the results, and wrote the paper along with Jenna Golan.

**Funding**

The Trial of Vitamins study was sponsored by the National Institute of Child Health and Human Development (NICHD R01 32257) and the Fogarty International Center (NIH D43 TW00004). RMZ was supported in part by an NIH T32 training grant (CA 09001).

**Acknowledgments**

The authors would like to thank James Okuma and Ellen Hertzmark who helped them access and analyze the data. They would also like to thank everyone who conducted the study and the women who participated in it.

**References**

[1] J. E. Lawn, S. Cousens, and J. Zupan, “4 Million neonatal deaths: when? Where? Why?” *The Lancet*, vol. 365, no. 9462, pp. 891–900, 2005.

[2] C. Mathers, G. Stevens, and M. Mascarenhas, *Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks*, World Health Organization, 2009.

[3] R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” *The Lancet*, vol. 380, no. 9859, pp. 2095–2128, 2012.

[4] S. Beck, D. Wojdyla, L. Say et al., “The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity,” *Bulletin of the World Health Organization*, vol. 88, no. 1, pp. 31–38, 2010.

[5] K. Manji, “Situation analysis of newborn health in Tanzania: current situation, existing plans and strategic next steps for newborn health,” 2009.

[6] C. Klingenberg, R. Olomi, M. Oneko, N. Sam, and N. Langland, “Neonatal morbidity and mortality in a Tanzanian tertiary care referral hospital,” *Annals of Tropical Paediatrics*, vol. 23, no. 4, pp. 293–299, 2003.

[7] L. K. Rogers and M. Velten, “Maternal inflammation, growth retardation, and preterm birth: insights into adult cardiovascular disease,” *Life Sciences*, vol. 89, no. 13-14, pp. 417–421, 2011.

[8] G. Filler, A. Yasin, P. Kesarwani, A. X. Garg, R. Lindsay, and A. P. Sharma, “Big mother or small baby: which predicts hypertension?” *Journal of Clinical Hypertension*, vol. 13, no. 1, pp. 35–41, 2011.

[9] Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), and Macro International, “Tanzania HIV/AIDS and Malaria Indicator Survey 2007-2008,” 2008.

[10] R. Lozano, H. Wang, K. J. Foreman et al., “Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis,” *The Lancet*, vol. 378, no. 9797, pp. 1159–1165, 2011.

[11] C. Mathers, G. Stevens, and M. Mascarenhas, “Global Health Risks: mortality and burden of disease attributable to selected major risks,” Tech. Rep., WHO, 2009.

[12] W. W. Fawzi, G. I. Msamanga, D. Spiegelman et al., “Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania,” *The Lancet*, vol. 351, no. 9114, pp. 1477–1482, 1998.

[13] W. W. Fawzi, G. I. Msamanga, D. Spiegelman et al., “A randomised trial of multivitamin supplements and HIV disease progression and mortality,” *The New England Journal of Medicine*, vol. 351, no. 1, pp. 23–32, 2004.

[14] W. W. Fawzi, G. I. Msamanga, D. Hunter et al., “Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality,” *AIDS*, vol. 16, no. 14, pp. 1935–1944, 2002.

[15] W. W. Fawzi, G. Msamanga, D. Hunter et al., “Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 23, no. 3, pp. 246–254, 2000.

[16] B. de Benoist, E. McLean, I. Egli, and M. Cogswell, *Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia*, WHO, Geneva, Switzerland, 2008.

[17] X. Guo, X. Zhang, L. Guo et al., “Association between prehypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies,” *Current Hypertension Reports*, vol. 15, pp. 703–716, 2013.

[18] E. Villamor, G. Msamanga, D. Spiegelman et al., “Effect of multivitamin and vitamin A supplements on weight gain during pregnancy among HIV-1-infected women,” *The American Journal of Clinical Nutrition*, vol. 76, no. 5, pp. 1082–1090, 2002.
[19] E. Villamor, M. L. Dreyfuss, A. Baylin, G. Msamanga, and W. W. Fawzi, "Weight loss during pregnancy is associated with adverse pregnancy outcomes among HIV-1 infected women," *Journal of Nutrition*, vol. 134, no. 6, pp. 1424–1431, 2004.

[20] E. Villamor, E. Saathoff, G. Msamanga, M. E. O’Brien, K. Manji, and W. W. Fawzi, "Wasting during pregnancy increases the risk of mother-to-child HIV-1 transmission," *Journal of Acquired Immune Deficiency Syndromes*, vol. 38, no. 5, pp. 622–626, 2005.

[21] O. S. Miettinen, *Theoretical Epidemiology: Principles of Occurrence Research in Medicine*, Delmar, 1985.

[22] D. Spiegelman and E. Hertzmark, "Easy SAS calculations for risk or prevalence ratios and differences," *The American Journal of Epidemiology*, vol. 162, no. 3, pp. 199–200, 2005.

[23] G. Maldonado and S. Greenland, "Simulation study of confounder-selection strategies," *The American Journal of Epidemiology*, vol. 138, no. 11, pp. 923–936, 1993.

[24] K. J. Rothman, S. Greenland, and T. L. Lash, *Modern Epidemiology*, Lippincott Williams & Wilkins, 2008.

[25] F. Martin and G. P. Taylor, "The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is "the more the merrier"?" *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 5, pp. 895–900, 2009.

[26] F. Mrisho, "Country Progress Reporting 2012".

[27] W. Y. N. Man, H. Worth, A. Kelly, D. P. Wilson, and P. Siba, "Is endemic political corruption hampering provision of ART and PMTCT in developing countries?" *Journal of the International AIDS Society*, vol. 17, Article ID 18556, 2014.

[28] WHO, UNICEF, and UNAIDS, "Global update on HIV treatment 2013: results, impact and opportunities," WHO Report in Partnership with UNICEF and UNAIDS, 2013.

[29] E. du Plessis, S. Y. Shaw, M. Gichuhi et al., "Prevention of mother-to-child transmission of HIV in Kenya: challenges to implementation," *BMC Health Services Research*, vol. 14, article S10, 2014.

[30] O. C. Ezechi, A. N. David, C. V. Gab-Okafor et al., "Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women," *BMC Pregnancy and Childbirth*, vol. 12, article 93, 2012.

[31] R. Martin, P. Boyer, H. Hammill et al., "Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers," *Journal of Pediatrics*, vol. 131, no. 6, pp. 851–856, 1997.

[32] J. Ndirangu, M.-L. Newell, R. M. Bland, and C. Thorne, "Maternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa," *Human Reproduction*, vol. 27, no. 6, pp. 1846–1856, 2012.

[33] L. Yu, W.-Y. Li, R. Y. Chen et al., "Pregnancy outcomes and risk factors for low birth weight and preterm delivery among HIV-infected pregnant women in Guangxi, China," *Chinese Medical Journal*, vol. 125, no. 3, pp. 403–409, 2012.

[34] E. J. Kongnyuy, P. N. Nana, N. Foumou, S. C. Wiysonge, L. Kouam, and A. S. Doh, "Adverse perinatal outcomes of adolescent pregnancies in cameroon," *Maternal and Child Health Journal*, vol. 12, no. 2, pp. 149–154, 2008.

[35] S. A. Feresu, S. D. Harlow, and G. B. Woelk, "Risk factors for prematurity at Harare Maternity Hospital, Zimbabwe," *International Journal of Epidemiology*, vol. 33, no. 6, pp. 1194–1201, 2004.

[36] U. Kuyumcuoglu, A. I. Guzel, and Y. Çelik, "Comparison of the risk factors for adverse perinatal outcomes in adolescent age pregnancies and advanced age pregnancies," *Ginekologia Polska*, vol. 83, no. 1, pp. 33–37, 2012.

[37] M. M. Hillemeier, C. S. Weisman, G. A. Chase, and A.-M. Dyer, "Individual and community predictors of preterm birth and low birthweight along the rural-urban continuum in central Pennsylvania," *Journal of Rural Health*, vol. 23, no. 1, pp. 42–48, 2007.